- Home
- DGICB vs CSTL Comparison
DGICB vs CSTL Comparison
Compare DGICB & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DGICB | CSTL |
|---|---|---|
| Founded | 1986 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 889.2M | 722.8M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DGICB | CSTL |
|---|---|---|
| Price | $19.40 | $34.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 1.1K | ★ 281.0K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $978,014,322.00 | $344,229,000.00 |
| Revenue This Year | $2.26 | $2.42 |
| Revenue Next Year | N/A | $12.69 |
| P/E Ratio | $8.06 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $14.87 | $17.72 |
| 52 Week High | $29.99 | $44.28 |
Technical Indicators
Market Signals| Indicator | DGICB | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.